Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. more
Time Frame | VERA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.42% | -3.39% | 0.2% |
1-Month Return | -2.01% | -1.92% | 2.72% |
3-Month Return | 9.72% | -10.54% | 7.31% |
6-Month Return | 22.93% | -4.47% | 10.44% |
1-Year Return | 180.75% | 4.06% | 27.53% |
3-Year Return | 77.49% | 0.94% | 30.88% |
5-Year Return | 281.83% | 36.67% | 89.21% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | 1.86M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 509.00K | 251.00K | 176.00K | (846.00K) | (1.86M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":49.31,"profit":true},{"date":"2021-12-31","value":34.58,"profit":true},{"date":"2022-12-31","value":-166.21,"profit":false},{"date":"2023-12-31","value":-365.82,"profit":false}] |
Gross Profit | (509.00K) | (251.00K) | (176.00K) | 846.00K | 1.86M | [{"date":"2019-12-31","value":-27.34,"profit":false},{"date":"2020-12-31","value":-13.48,"profit":false},{"date":"2021-12-31","value":-9.45,"profit":false},{"date":"2022-12-31","value":45.44,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | - | - | - | - | 100.00% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 11.70M | 49.24M | 34.40M | 90.90M | 102.01M | [{"date":"2019-12-31","value":11.47,"profit":true},{"date":"2020-12-31","value":48.27,"profit":true},{"date":"2021-12-31","value":33.72,"profit":true},{"date":"2022-12-31","value":89.11,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (11.96M) | (52.24M) | (34.40M) | (90.90M) | (102.01M) | [{"date":"2019-12-31","value":-1196100000,"profit":false},{"date":"2020-12-31","value":-5224100000,"profit":false},{"date":"2021-12-31","value":-3440200000,"profit":false},{"date":"2022-12-31","value":-9090300000,"profit":false},{"date":"2023-12-31","value":-10201200000,"profit":false}] |
Total Non-Operating Income/Expense | 216.00K | (1.27M) | 1.79M | 2.61M | 9.61M | [{"date":"2019-12-31","value":2.25,"profit":true},{"date":"2020-12-31","value":-13.18,"profit":false},{"date":"2021-12-31","value":18.62,"profit":true},{"date":"2022-12-31","value":27.13,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (11.85M) | (53.41M) | (32.61M) | (89.06M) | (95.99M) | [{"date":"2019-12-31","value":-1185300000,"profit":false},{"date":"2020-12-31","value":-5341200000,"profit":false},{"date":"2021-12-31","value":-3260800000,"profit":false},{"date":"2022-12-31","value":-8905500000,"profit":false},{"date":"2023-12-31","value":-9598900000,"profit":false}] |
Income Taxes | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (11.85M) | (53.41M) | (32.61M) | (89.06M) | (95.99M) | [{"date":"2019-12-31","value":-1185400000,"profit":false},{"date":"2020-12-31","value":-5341300000,"profit":false},{"date":"2021-12-31","value":-3260900000,"profit":false},{"date":"2022-12-31","value":-8905600000,"profit":false},{"date":"2023-12-31","value":-9599000000,"profit":false}] |
Income From Continuous Operations | (11.85M) | (53.41M) | (32.61M) | 89.06M | (102.77M) | [{"date":"2019-12-31","value":-13.31,"profit":false},{"date":"2020-12-31","value":-59.98,"profit":false},{"date":"2021-12-31","value":-36.62,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-115.4,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (11.85M) | (53.41M) | (32.61M) | (89.06M) | (95.99M) | [{"date":"2019-12-31","value":-1185400000,"profit":false},{"date":"2020-12-31","value":-5341300000,"profit":false},{"date":"2021-12-31","value":-3260900000,"profit":false},{"date":"2022-12-31","value":-8905600000,"profit":false},{"date":"2023-12-31","value":-9599000000,"profit":false}] |
EPS (Diluted) | - | - | (14.21) | (3.35) | (2.31) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-1420.53,"profit":false},{"date":"2022-12-31","value":-335,"profit":false},{"date":"2023-12-31","value":-231,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
VERA | |
---|---|
Cash Ratio | 13.35 |
Current Ratio | 13.76 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
VERA | |
---|---|
ROA (LTM) | -33.37% |
ROE (LTM) | -65.11% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
VERA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.22 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.78 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
VERA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 9.63 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Vera Therapeutics Inc (VERA) share price today is $41.281
Yes, Indians can buy shares of Vera Therapeutics Inc (VERA) on Vested. To buy Vera Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VERA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Vera Therapeutics Inc (VERA) via the Vested app. You can start investing in Vera Therapeutics Inc (VERA) with a minimum investment of $1.
You can invest in shares of Vera Therapeutics Inc (VERA) via Vested in three simple steps:
The 52-week high price of Vera Therapeutics Inc (VERA) is $51.61. The 52-week low price of Vera Therapeutics Inc (VERA) is $14.2.
The price-to-earnings (P/E) ratio of Vera Therapeutics Inc (VERA) is
The price-to-book (P/B) ratio of Vera Therapeutics Inc (VERA) is 9.63
The dividend yield of Vera Therapeutics Inc (VERA) is 0.00%
The market capitalization of Vera Therapeutics Inc (VERA) is $2.78B
The stock symbol (or ticker) of Vera Therapeutics Inc is VERA